Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velcade in Metastatic Malignant Melanoma
NCT00024011Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2001
- Primary completion
- Sep 2006
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in melanoma, sponsored by National Cancer Institute. Primary endpoint: Progression-Free Survival at 18 weeks. Started Jul 2001; status: completed.
02
Drugs
bortezomib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00024011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00024011.